Ascendis Pharma A/S (ASND): who owns it and who trades it
As of Nov 16, 2026, ASND insiders reported 3 open-market sales worth $5.5M and 9 purchases worth $777K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Flemming Steen Jensen (See Remarks), with $4.6M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ascendis Pharma A/S
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ASND
301 funds and institutions reported ASND shares worth $17.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 16.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.28M | 16.59% | $2.7B | No change |
| T. Rowe Price Investment Management, Inc. | 6.75M | 10.90% | $1.8B | – |
| Avoro Capital Advisors LLC | 5.11M | 8.25% | $1.4B | +1% |
| Westfield Capital Management Co LP | 4.80M | 7.74% | $1.3B | -0% |
| Jupiter Topco LLC | 3.65M | 5.89% | $973M | – |
| FMR LLC (Fidelity) | 3.55M | 5.72% | $946M | -9% |
| Artisan Partners Limited Partnership | 2.63M | 4.25% | $703M | -18% |
| BlackRock, Inc. | 2.21M | 3.57% | $590M | +235% |
| Capital International Investors | 1.99M | 3.21% | $530M | +2% |
| Massachusetts Financial Services Co | 1.88M | 3.03% | $500M | +1% |
| Franklin Resources Inc | 1.86M | 3.01% | $497M | -9% |
| Wellington Management Group LLP | 1.55M | 2.50% | $413M | -12% |
| American Century Companies Inc | 1.40M | 2.26% | $374M | +0% |
| Perceptive Advisors LLC | 1.16M | 1.88% | $310M | -24% |
| T. Rowe Price Associates | 1.12M | 1.81% | $299M | – |
| Capital World Investors | 906,081 | 1.46% | $242M | +1% |
| Principal Financial Group Inc | 873,502 | 1.41% | $233M | -3% |
| Polar Capital Holdings Plc | 616,908 | 1.00% | $165M | -5% |
| Goldman Sachs Group Inc | 559,534 | 0.90% | $149M | -1% |
| Morgan Stanley | 544,393 | 0.88% | $145M | -10% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ASND insiders reported $777K of open-market purchases and $5.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Mads Bodenhoff | Vice president | Sale | 3,000 | $270.19 | $811K | Form 4 |
| Sep 2, 2026 | Lars Holtug | Director | Sale | 236 | $264.13 | $62.3K | Form 4 |
| Aug 14, 2026 | Jean Jacques Bienaime | Director | Purchase | 1,100 | $245.85 | $270K | Form 4 |
| Aug 14, 2026 | Jean Jacques Bienaime | Director | Purchase | 900 | $246.91 | $222K | Form 4 |
| Jun 2, 2026 | Scott Thomas Smith | CFO | Purchase | 100 | $219.00 | $21.9K | Form 4 |
| May 29, 2026 | Jean Jacques Bienaime | Director | Purchase | 200 | $223.76 | $44.8K | Form 4 |
| May 29, 2026 | Jean Jacques Bienaime | Director | Purchase | 100 | $223.50 | $22.4K | Form 4 |
| May 29, 2026 | Jean Jacques Bienaime | Director | Purchase | 200 | $222.30 | $44.5K | Form 4 |
| May 29, 2026 | Scott Thomas Smith | CFO | Purchase | 250 | $223.32 | $55.8K | Form 4 |
| May 26, 2026 | Jean Jacques Bienaime | Director | Purchase | 200 | $239.37 | $47.9K | Form 4 |
| May 26, 2026 | Jean Jacques Bienaime | Director | Purchase | 200 | $236.24 | $47.2K | Form 4 |
| May 11, 2026 | Flemming Steen Jensen | See Remarks | Sale | 19,460 | $238.49 | $4.6M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Flemming Steen Jensen | See Remarks | – | $4.6M | May 11, 2026 |
| Mads Bodenhoff | SVP & PAO | – | $811K | Sep 8, 2026 |
| Jean Jacques Bienaime | Director | $699K | – | Aug 14, 2026 |
| Scott Thomas Smith | EVP & Chief Financial Officer | $77.7K | – | Jun 2, 2026 |
| Lars Holtug | Director | – | $62.3K | Sep 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ASND short interest
3.00M ASND shares are sold short. Over the last 12 reports the number of shares short went up 74%.
As of Oct 30, 2026, 3.00M ASND shares were sold short, down 4.3% from the report before. At the average daily volume of 600,847 shares, buying them all back would take about 5.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.00M | – | -4% | 600,847 | 5.0 |
| Oct 15, 2026 | 3.13M | – | -10% | 755,159 | 4.2 |
| Sep 30, 2026 | 3.48M | – | -12% | 937,174 | 3.7 |
| Sep 15, 2026 | 3.96M | – | -6% | 808,088 | 4.9 |
| Aug 31, 2026 | 4.20M | – | +14% | 442,630 | 9.5 |
| Aug 14, 2026 | 3.69M | – | +8% | 589,552 | 6.2 |
| Jul 31, 2026 | 3.40M | – | +10% | 472,453 | 7.2 |
| Jul 15, 2026 | 3.10M | 5.01% | -5% | 552,854 | 5.6 |
| Jun 30, 2026 | 3.28M | 5.29% | +65% | 1.30M | 2.5 |
| Jun 15, 2026 | 1.99M | 3.21% | +16% | 576,428 | 3.5 |
| May 29, 2026 | 1.72M | 2.78% | -0% | 555,522 | 3.1 |
| May 15, 2026 | 1.72M | 2.78% | -39% | 623,378 | 2.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Famous investors that hold ASND
4 of the 50 well-known investors we track reported holding ASND in their latest 13F filing. The largest position is Israel Englander's, worth $26.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 115,640 | $26.3M | 0.0% | -57% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 95,199 | $21.7M | 0.0% | -20% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 22,920 | $5.2M | 0.0% | -83% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 19,296 | $4.4M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ASND in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 12.4% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 12.4% |
| Nov 5, 2026 | FMR LLC | 13G/A | 5.2% |
| Nov 5, 2026 | FMR LLC | 13G/A | 5.2% |
Questions about Ascendis Pharma A/S (ASND) stock
Who owns the most ASND stock?
The largest reported owner of Ascendis Pharma A/S (ASND) is Ra Capital Management, L.P., with 16.6% of the company. In total, 301 funds and institutions reported holding ASND at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ASND insiders buying or selling?
In the last 12 months, ASND insiders reported 9 open-market purchases worth $777K and 3 sales worth $5.5M. The latest trade was on Sep 8, 2026. See every trade.
What is the short interest in ASND?
As of Oct 30, 2026, 3.00M ASND shares were sold short, down 4.3% from the report before. At the average daily volume of 600,847 shares, buying them all back would take about 5.0 trading days (days to cover). See the history.
Which famous investors hold ASND?
4 of the 50 well-known investors we track reported ASND in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $26.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.